References

1. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD Jr, 1989. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83 : 860–864.
   [Google Scholar]
2. Khalil EAG, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, Elhassan IM, Smith PG, Kieny PM, Ghalib HW, Zicker F, Modabber F, Elhassan AM, 2005. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 140 : 349–353.
   [Google Scholar]
3. Desjeux P, 1992. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q 45 : 267–275.
   [Google Scholar]
4. Sacks DL, Lal SL, Shrivastava SN, Blackwell JM, Neva FA, 1987. An analysis of T cell responsiveness in Indian Kala-azar. J Immunol 138 : 908–913.
   [Google Scholar]
5. Zijlstra EE, El-Hassan AM, Ismail A, Ghalib HW, 1994. Endemic Kalaazar in eastern Sudan: a longitudinal study of the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51 : 826–836.
   [Google Scholar]
6. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, Michalick MS, Williams P, Lima AO, Vieira JB, 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15 : 572–580.
   [Google Scholar]
7. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F, 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 356 : 1565–1569.
   [Google Scholar]
8. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Labaf-Ghasemi R, 1999. A randomized double-blind, controlled trial of killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17 : 466–472.
   [Google Scholar]
9. Zhou XH, Obuchowski NA, McClish DK, 2002. Statistical Methods in Diagnostic Medicine. New York: Wiley & Sons.
10. Sokal JE, 1975. Editorial: Measurement of delayed skin-test responses. N Engl J Med 293 : 501–502.
    [Google Scholar]
11. Manson-Bahr PEC, 1961. Immunity in kala-azar. Trans R Soc Trop Med Hyg 55 : 550–555.
    [Google Scholar]
12. el Safi S, Hamid N, Ahmad-Haleem OA, Hammad A, Kareem HG, Boelaert M, 2004. Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan. Trop Med Int Health 9 : 1305–1311.
    [Google Scholar]
13. Bern C, Amann J, Haque R, Chowdhury AM, Kurkjian KM, Vaz L, Wagatsuma Y, Breiman RF, Secor WE, Maguire JH, 2006. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 75 : 744–748.
    [Google Scholar]
14. Mol CJ, Koethe SM, 2006. QuantiFERON TB GOLD: an innovation in tuberculosis screening. Aaohn J 54 : 245–247.
    [Google Scholar]
15. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri S, 2006. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occupat Med Toxicol 1 : 7.
    [Google Scholar]